Advertisement

Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer

  • Gargi Kothari
  • Piet Ost
  • Patrick Cheung
  • Pierre Blanchard
  • Alison C. Tree
  • Nicholas J. van As
  • Simon S. Lo
  • Drew Moghanaki
  • Andrew Loblaw
  • Shankar SivaEmail author
Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Genitourinary Cancers

Abstract

Purpose of Review

Systemic therapy for patients with hormone-sensitive oligometastatic prostate cancer is non-curative and associated with toxicities. Meanwhile, this population presents unique clinical opportunities to improve outcomes, including the demonstrated benefits of radiotherapy to the primary tumor or oligometastatic sites.

Recent Findings

Recently published randomized studies have demonstrated benefits with the addition of radiotherapy to the primary disease or metastatic lesions in patients with synchronous or metachronous disease. The introduction of novel PET imaging has improved the sensitivity and specificity for detecting metastatic disease and provides an opportunity to better select patients who will benefit from local therapy.

Summary

The data presented in this review supports revisiting practice guidelines for patients with hormone-sensitive metastatic prostate cancer, particularly in relation to the role of radiotherapy to the primary tumor and sites of oligometastatic disease. Future trials will aim to further establish the role of metastasis-directed therapies in metachronous, synchronous, and castrate-resistant disease.

Keywords

Oligometastases Metastasis directed therapy SBRT Prostate cancer 

Notes

Funding Information

Alison C. Tree and Nicholas J. van As “This paper represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.”

Compliance with Ethical Standards

Conflict of Interest

Gargi Kothari declares that he has no conflict of interest.

Piet Ost declares that he has no conflict of interest.

Patrick Cheung is supported by an investigator-initiated industry research grant (to fund a current Phase I/II trial in hormone-sensitive oligometastatic prostate cancer) from AbbVie.

Pierre Blanchard has received research support through grants from Astellas and Amgen.

Alison C. Tree has received research support through grants from MSD and Elekta, and has received compensation from Bayer, Astellas, Janssen, and Ferring Pharmaceuticals for service as a consultant.

Nicholas J. van As has received both research grants as well as compensation for service as a consultant from Accuray.

Simon S. Lo served as an expert group member for the Elekta ICON and also received partial research support from Elekta for the International Oligometastasis Consortium (ended in July 2016).

Drew Moghanaki has received reimbursement for travel expenses and compensation for service as a consultant from Varian Medical Systems.

Andrew Loblaw has received research support through grants from AbbVie, Astellas, Janssen, Sanofi, AstraZeneca, and TerSera Therapeutics; has received compensation from AbbVie, Bayer, Astellas, Janssen, Sanofi, AstraZeneca, and TerSera Therapeutics for service as a consultant; has received non-financial support from Astellas, Janssen, AstraZeneca, and TerSera Therapeutics; and has a patent issued on a prostate immobilization device.

Shankar Siva has received research support through grants from Varian Medical Systems and MSD; has received compensation from AstraZeneca, Bristol-Myers Squibb, Astellas, Roche, and Janssen for service on advisory boards; and has received reimbursement for travel expenses from AstraZeneca Bristol-Myers Squibb, and Astellas.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.CrossRefGoogle Scholar
  2. 2.
    Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15–25.  https://doi.org/10.1038/nrurol.2016.175.CrossRefPubMedGoogle Scholar
  3. 3.
    Lecouvet FE, Oprea-Lager DE, Liu Y, Ost P, Bidaut L, Collette L, et al. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC imaging group. Lancet Oncol. 2018;19(10):e534–e45.  https://doi.org/10.1016/s1470-2045(18)30571-0.CrossRefPubMedGoogle Scholar
  4. 4.
    Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol Biol Phys. 2018;102(3):S3–4.  https://doi.org/10.1016/j.ijrobp.2018.06.105.CrossRefGoogle Scholar
  5. 5.
    Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353–7.  https://doi.org/10.1038/nature14347.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hong MK, Macintyre G, Wedge DC, Van Loo P, Patel K, Lunke S, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 2015;6:6605.  https://doi.org/10.1038/ncomms7605.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    • Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, Multicenter Phase II. Trial J Clin Oncol. 2018;36(5):446–53.  https://doi.org/10.1200/JCO.2017.75.4853 First randomized Phase II trial of observation versus metastasis directed therapy in patients with hormone sensitive oligometastatic prostate cancer which showed improved ADT-free survival in metastasis directed therapy arm (21 vs 13 months, HR 0.60, 80% CI 0.40–0.90, p = 0.11). CrossRefPubMedGoogle Scholar
  8. 8.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.  https://doi.org/10.3322/caac.21387.CrossRefPubMedGoogle Scholar
  9. 9.
    Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73(4):560–9.  https://doi.org/10.1016/j.eururo.2017.12.018.CrossRefPubMedGoogle Scholar
  10. 10.
    James ND, Spears MR, Clarke NW, Dearnaley DP, Mason MD, Parker CC, et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol. 2016;2(3):348–57.  https://doi.org/10.1001/jamaoncol.2015.4350.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, et al. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014;88(5):1064–73.  https://doi.org/10.1016/j.ijrobp.2014.01.008.CrossRefPubMedGoogle Scholar
  12. 12.
    Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.  https://doi.org/10.1056/NEJMoa1503747.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–7.  https://doi.org/10.1200/JCO.2017.75.3657.CrossRefPubMedGoogle Scholar
  14. 14.
    James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.  https://doi.org/10.1016/S0140-6736(15)01037-5.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.  https://doi.org/10.1056/NEJMoa1702900.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.  https://doi.org/10.1056/NEJMoa1704174.CrossRefGoogle Scholar
  17. 17.
    Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, Lambert B, et al. Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al. J Clin Oncol. 2018;36(22):2351–2.  https://doi.org/10.1200/JCO.2018.78.2144.CrossRefPubMedGoogle Scholar
  18. 18.
    Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2002;(1):CD003506.  https://doi.org/10.1002/14651858.CD003506.
  19. 19.
    Mottet N, van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, et al. EAU - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer 2018. European Association of Urology Guidelines. 2018 Edition. Arnhem: European Association of Urology Guidelines Office; 2018.Google Scholar
  20. 20.
    Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2016;17(6):727–37.  https://doi.org/10.1016/S1470-2045(16)00107-8.CrossRefPubMedGoogle Scholar
  21. 21.
    Frydenberg M, Woo HH. Early androgen deprivation therapy improves survival, but how do we determine in whom? Eur Urol. 2018;73(4):519–20.  https://doi.org/10.1016/j.eururo.2018.01.004.CrossRefPubMedGoogle Scholar
  22. 22.
    Sumanasuriya S, De Bono J. Treatment of advanced prostate cancer—a review of current therapies and future promise. Cold Spring Harb Perspect Med. 2018;8(6):a030635.CrossRefGoogle Scholar
  23. 23.
    Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.  https://doi.org/10.1056/NEJMoa003013.CrossRefPubMedGoogle Scholar
  24. 24.
    Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004;22(17):3475–84.  https://doi.org/10.1200/JCO.2004.10.218.CrossRefPubMedGoogle Scholar
  25. 25.
    Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123(11):4918–22.  https://doi.org/10.1172/JCI70354.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009;9(4):285–93.  https://doi.org/10.1038/nrc2621.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–26.  https://doi.org/10.1016/j.cell.2009.11.025.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    • Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol. 2018.  https://doi.org/10.1016/j.eururo.2018.09.008 First randomized Phase III trial of ADT +/− prostate radiotherapy in patients with synchronous oligometastatic prostate cancer, which showed an overall survival benefit to the addition of radiotherapy, although this was not statistically significant. An unplanned subgroup analysis showed a greater effect size for survival in patients with low volume metastatic disease (not statistically significant).
  29. 29.
    • Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66.  https://doi.org/10.1016/S0140-6736(18)32486-3 Randomized Phase III trial of ADT +/- prostate radiotherapy which showed a statistically significant overall survival benefit in patients with low volume metastatic disease.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.  https://doi.org/10.1016/j.eururo.2013.11.012.CrossRefPubMedGoogle Scholar
  31. 31.
    Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol. 2015;194(2):378–85.  https://doi.org/10.1016/j.juro.2015.02.084.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Loppenberg B, Dalela D, Karabon P, Sood A, Sammon JD, Meyer CP, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a National Cancer Data Base Analysis. Eur Urol. 2017;72(1):14–9.  https://doi.org/10.1016/j.eururo.2016.04.031.CrossRefPubMedGoogle Scholar
  33. 33.
    Leyh-Bannurah SR, Gazdovich S, Budaus L, Zaffuto E, Briganti A, Abdollah F, et al. Local therapy improves survival in metastatic prostate cancer. Eur Urol. 2017;72(1):118–24.  https://doi.org/10.1016/j.eururo.2017.03.020.CrossRefPubMedGoogle Scholar
  34. 34.
    Jang WS, Kim MS, Jeong WS, Chang KD, Cho KS, Ham WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int. 2018;121(2):225–31.  https://doi.org/10.1111/bju.13992.CrossRefPubMedGoogle Scholar
  35. 35.
    Pompe RS, Tilki D, Preisser F, Leyh-Bannurah SR, Bandini M, Marchioni M, et al. Survival benefit of local versus no local treatment for metastatic prostate cancer-impact of baseline PSA and metastatic substages. Prostate. 2018;78(10):753–7.  https://doi.org/10.1002/pros.23519.CrossRefPubMedGoogle Scholar
  36. 36.
    Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;67(1):3–6.  https://doi.org/10.1016/j.eururo.2014.08.056.CrossRefPubMedGoogle Scholar
  37. 37.
    Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med. 2012;2012:261096.  https://doi.org/10.1155/2012/261096.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, et al. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate. 2014;74(3):297–305.  https://doi.org/10.1002/pros.22750.CrossRefPubMedGoogle Scholar
  39. 39.
    De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G, et al. Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. BJU Int. 2017;120(6):815–21.  https://doi.org/10.1111/bju.13938.CrossRefPubMedGoogle Scholar
  40. 40.
    Porres D, Pfister D, Thissen A, Kuru TH, Zugor V, Buettner R, et al. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. Prostate Cancer Prostatic Dis. 2017;20(1):85–92.  https://doi.org/10.1038/pcan.2016.54.CrossRefPubMedGoogle Scholar
  41. 41.
    Zattoni F, Nehra A, Murphy CR, Rangel L, Mynderse L, Lowe V, et al. Mid-term outcomes following salvage lymph node dissection for prostate cancer nodal recurrence status post–radical prostatectomy. Eur Urol Focus. 2016;2(5):522–31.CrossRefGoogle Scholar
  42. 42.
    Oderda M, Joniau S, Melloni G, Falcone M, Munegato S, Tosco L, et al. Outcomes of salvage lymph node dissection for prostate cancer with clinical nodal relapse: results of a multicentric, retrospective study. EMJ. 2016;1(2):108–15.Google Scholar
  43. 43.
    Montorsi F, Gandaglia G, Fossati N, Suardi N, Pultrone C, De Groote R, et al. Robot-assisted salvage lymph node dissection for clinically recurrent prostate cancer. Eur Urol. 2017;72(3):432–8.  https://doi.org/10.1016/j.eururo.2016.08.051.CrossRefPubMedGoogle Scholar
  44. 44.
    Osmonov DK, Aksenov AV, Trick D, Naumann CM, Hamann MF, Faddan AA, et al. Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection. BMC Urol. 2016;16(1):56.CrossRefGoogle Scholar
  45. 45.
    Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67(2):299–309.  https://doi.org/10.1016/j.eururo.2014.02.011.CrossRefPubMedGoogle Scholar
  46. 46.
    Tilki D, Mandel P, Seeliger F, Kretschmer A, Karl A, Ergun S, et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol. 2015;193(2):484–90.  https://doi.org/10.1016/j.juro.2014.08.096.CrossRefPubMedGoogle Scholar
  47. 47.
    Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60(5):935–43.  https://doi.org/10.1016/j.eururo.2011.07.060.CrossRefPubMedGoogle Scholar
  48. 48.
    Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, et al. Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis. Eur Urol. 2019;75(1):176–83.  https://doi.org/10.1016/j.eururo.2018.09.009.CrossRefPubMedGoogle Scholar
  49. 49.
    Jilg CA, Rischke HC, Reske SN, Henne K, Grosu AL, Weber W, et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol. 2012;188(6):2190–7.  https://doi.org/10.1016/j.juro.2012.08.041.CrossRefPubMedGoogle Scholar
  50. 50.
    Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B, et al. Exploring all avenues for radiotherapy in oligorecurrent prostate cancer disease limited to lymph nodes: a systematic review of the role of stereotactic body radiotherapy. Eur Urol Focus. 2017;3(6):538–44.CrossRefGoogle Scholar
  51. 51.
    • Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455–62.  https://doi.org/10.1016/j.eururo.2018.06.004 Single arm prospective trial of single fraction SBRT in patients with hormone sensitive oligometastatic prostate cancer, which showed 2-year local PFS of 93%, 2-year distant PFS of 39% and 2-year ADT-free survival of 48%. CrossRefPubMedGoogle Scholar
  52. 52.
    • Tran P, Radwan N, Phillips R, Ross A, Rowe S, Gorin M, et al. OC-0505: interim results of a randomized trial of observation versus SABR for oligometastatic prostate cancer. Radiother Oncol. 2018;127:S261.  https://doi.org/10.1016/s0167-8140(18)30815-6 Interim results of phase II randomized trial of observation versus SBRT for hormone sensitive oligometastatic prostate cancer showed progression at 6 months of 67% in observation versus 33% in SBRT arm. CrossRefGoogle Scholar
  53. 53.
    Vilela RA, Navarro NF, Faria ET, Ferreira EB, Ruzza RZ, Gadia R, et al. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: a systematic review. J Med Imaging Radiat Oncol. 2018;62(5):692–706.  https://doi.org/10.1111/1754-9485.12747.CrossRefPubMedGoogle Scholar
  54. 54.
    Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852–63.  https://doi.org/10.1016/j.eururo.2014.09.004.CrossRefPubMedGoogle Scholar
  55. 55.
    Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, et al. Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. 2018;1(6):531–7.  https://doi.org/10.1016/j.euo.2018.04.017.CrossRefGoogle Scholar
  56. 56.
    Moghanaki D, Turkbey B, Vapiwala N, Ehdaie B, Frank SJ, McLaughlin PW, et al. Advances in prostate cancer magnetic resonance imaging and positron emission tomography-computed tomography for staging and radiotherapy treatment planning. Semin Radiat Oncol. 2017;27(1):21–33.  https://doi.org/10.1016/j.semradonc.2016.08.008.CrossRefPubMedGoogle Scholar
  57. 57.
    Hövels A, Heesakkers R, Adang E, Jager G, Strum S, Hoogeveen Y, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63(4):387–95.CrossRefGoogle Scholar
  58. 58.
    Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skelet Radiol. 2014;43(11):1503–13.  https://doi.org/10.1007/s00256-014-1903-9.CrossRefGoogle Scholar
  59. 59.
    Evangelista L, Bertoldo F, Boccardo F, Conti G, Menchi I, Mungai F, et al. Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. Eur J Nucl Med Mol Imaging. 2016;43(8):1546–62.  https://doi.org/10.1007/s00259-016-3350-4.CrossRefPubMedGoogle Scholar
  60. 60.
    Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ, et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016;43(1):55–69.  https://doi.org/10.1007/s00259-015-3202-7.CrossRefPubMedGoogle Scholar
  61. 61.
    Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2010;12(1):98–107.CrossRefGoogle Scholar
  62. 62.
    Schwarzenböck S, Souvatzoglou M, Krause B. Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics. 2012;2(3):318–30.CrossRefGoogle Scholar
  63. 63.
    Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, et al. (68)Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. 2017;58(10):1617–23.  https://doi.org/10.2967/jnumed.117.190827.CrossRefPubMedGoogle Scholar
  64. 64.
    Corfield J, Perera M, Bolton D, Lawrentschuk N. (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol. 2018;36(4):519–27.  https://doi.org/10.1007/s00345-018-2182-1.CrossRefPubMedGoogle Scholar
  65. 65.
    Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(6):926–37.CrossRefGoogle Scholar
  66. 66.
    Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of (68)Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study. J Nucl Med. 2018;59(1):82–8.  https://doi.org/10.2967/jnumed.117.197160.CrossRefPubMedGoogle Scholar
  67. 67.
    Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a meta-analysis comparing (1)(8)FDG PET, CT, MRI and bone scintigraphy. Eur Radiol. 2011;21(12):2604–17.  https://doi.org/10.1007/s00330-011-2221-4.CrossRefPubMedGoogle Scholar
  68. 68.
    Liu LP, Cui LB, Zhang XX, Cao J, Chang N, Tang X, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bone malignancy: evidence from a meta-analysis. Medicine (Baltimore). 2015;94(45):e1998.  https://doi.org/10.1097/MD.0000000000001998.CrossRefGoogle Scholar
  69. 69.
    Xu GZ, Li CY, Zhao L, He ZY. Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis. Ann Oncol. 2013;24(1):96–101.  https://doi.org/10.1093/annonc/mds234.CrossRefPubMedGoogle Scholar
  70. 70.
    Lohaus F, Zophel K, Lock S, Wirth M, Kotzerke J, Krause M, et al. Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease? Eur Urol. 2018.  https://doi.org/10.1016/j.eururo.2018.11.050.
  71. 71.
    Sooriakumaran P. Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial. BJU Int. 2017;120(5B):E8–E20.  https://doi.org/10.1111/bju.13925.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Gargi Kothari
    • 1
    • 2
  • Piet Ost
    • 3
  • Patrick Cheung
    • 4
  • Pierre Blanchard
    • 5
  • Alison C. Tree
    • 6
  • Nicholas J. van As
    • 6
  • Simon S. Lo
    • 7
  • Drew Moghanaki
    • 8
  • Andrew Loblaw
    • 4
  • Shankar Siva
    • 1
    • 2
    Email author
  1. 1.Sir Peter MacCallum Department of OncologyUniversity of MelbourneMelbourneAustralia
  2. 2.Peter MacCallum Cancer CenterMelbourneAustralia
  3. 3.Department of Radiation OncologyGhent University HospitalGhentBelgium
  4. 4.Department of Radiation Oncology, Sunnybrook Odette Cancer CentreUniversity of TorontoTorontoCanada
  5. 5.Gustave-Roussy, Radiotherapy DepartmentParis-Saclay UniversityVillejuifFrance
  6. 6.Royal Marsden NHS Foundation Trust and the Institute of Cancer ResearchLondonUK
  7. 7.Department of Radiation OncologyUniversity of Washington School of MedicineSeattleUSA
  8. 8.Hunter Holmes McGuire VA Medical CenterVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations